Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 726 results for end of life care

  1. Seladelpar for previously treated primary biliary cholangitis (TA1171)

    Evidence-based recommendations on seladelpar (Livdelzi) for previously treated primary biliary cholangitis in adults.

  2. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  3. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  4. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (HTG530)

    Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.

  5. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  6. DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography (HTG594)

    Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.

  7. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

  8. Prognostic tools:- Is the amyotrophic lateral sclerosis (ALS) Prognostic Index an accurate predictor of survival in people with MND under NHS care in England and/or Wales?

    Prognostic Index an accurate predictor of survival in people with MND under NHS care in England and/or Wales? Any explanatory notes(if...

  9. Memokath 051 Ureter stent for ureteric obstruction (HTG651)

    Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.

  10. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  11. Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)

    Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.

  12. Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)

    Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.

  13. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

  14. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.